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ABSTRACT 
The use of aromatase inhibitors (AIs) has been associated with increased risk of 
cardiovascular disease and unfavorable changes in lipid profile in postmenopausal breast cancer 
survivors. In other populations, physical activity has been shown to successfully reduce CVD 
risk and improve lipid parameters. The Hormones and Physical Exercise (HOPE) study was a 
yearlong randomized trial examining the impact of exercise vs. usual care on AI-associated side 
effects. This analysis examined the effect of exercise on lipid profiles among HOPE participants. 
We enrolled 121 physically inactive (<90 min/wk of aerobic activity and no strength 
training) postmenopausal breast cancer survivors receiving an AI for at least 6 months. 
Participants were randomly assigned to exercise (150 min/wk of aerobic exercise and supervised 
strength training 2x/wk) or to usual care. Fasting blood samples (>12 hours) were collected at the 
baseline, 6- and 12-month clinic visits. Intervention effects were evaluated using generalized 
linear models, with change from baseline to 6 months and 12 months as the primary end points. 
Over 12 months, women randomized to exercise increased their exercise by 159 (SD 136) 
minutes per week and decreased their body weight by 2.4% (SD 5.4%). LDL/HDL ratio 
increased by 3% at 6 months among women randomized to exercise versus a 6% decrease among 
those in the attention control group (p = 0.036). Likewise, TC/HDL ratio increased by 2% at 6 
months among women randomized to exercise versus a 5% decrease among those in the attention 
control group (p = 0.038). A dose-response inverse relation between attendance to supervised 
exercise sessions and triglycerides was also observed (p = 0.047). 
We observed an unfavorable effect of exercise on the lipid ratios. Further research is 
needed to examine the impact of exercise on lipid levels and CVD risk in breast cancer survivors 
initiating AI use. 
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INTRODUCTION 
 Breast cancer is the most commonly diagnosed cancer and the second leading cause of 
cancer-related death among American women.1 In 2014, there were an estimated 232,670 
incident cases of breast cancer and 40,000 deaths due to breast cancer.2 Globally, breast cancer 
incidence increased by more than 20% between 2008 and 2012, with 1.67 million women 
diagnosed with breast cancer worldwide in 2012.3 More than half of breast cancer cases (52.8%) 
and deaths (62.1%) occurred in less developed countries, reflecting the shifting lifestyles in these 
regions, as well as lack of early detection leading to poorer survival.4 
 Due to improved survival resulting from earlier detection and treatment advances, there 
are an estimated 3.1 million breast cancer survivors in the U.S.5 More than two thirds of breast 
cancer cases are hormone receptor-positive and responsive to adjuvant endocrine therapy.6 
Tamoxifen has historically been the standard hormonal treatment for both pre- and 
postmenopausal women. However, third-generation aromatase inhibitors (AIs) - including 
exemestane, letrozole, and anastrozole - have increasingly been viewed as the standard of care 
for postmenopausal women, with several randomized trials demonstrating reduced recurrence 
rates and improved disease-free survival for AIs compared to 5 years of tamoxifen.7-11 Current 
guidelines recommend that postmenopausal women with hormone receptor-positive breast 
cancer receive an AI, either as primary therapy or following 2-5 years of tamoxifen.12 
 Two recent meta-analyses indicate that, compared with tamoxifen, the use of AIs in 
postmenopausal women is associated with a small increase in risk of developing cardiovascular 
disease (CVD).13,14 However, another recent review of AI trials showed no significantly 
increased risk of CVD events compared to placebo, indicating that increases in CVD risk with 
AIs compared to tamoxifen may have been confounded by the use of tamoxifen as a comparator, 
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due to the known cardioprotective effects of tamoxifen.15 The evidence on the effect of AIs on 
lipid profile is similarly mixed. Two recent randomized trials found overall unfavorable effects 
of AIs on lipid profile, although these findings may be explained in part by the withdrawal effect 
of tamoxifen. The MA-17L sub-study observed significant increases in total cholesterol, high-
density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol among 
postmenopausal women on letrozole after 5 years of tamoxifen.16 The ELPh trial compared 
treatment with exemestane (steroidal AI) to letrozole (non-steroidal AI), finding significant 
decreases in total cholesterol and HDL in the exemestane group and significant increases in total 
cholesterol and LDL in the letrozole group, as well as a significant increase in LDL/HDL ratio in 
the entire cohort.17 Given that CVD is the leading cause of death for breast cancer survivors and 
postmenopausal women are at an increased risk for CVD, these findings have important 
implications on the risk-benefit ratio of adjuvant treatment choice.18 
Effective interventions are therefore needed to reduce cardiovascular disease risk in 
breast cancer survivors. Physical activity may be an effective intervention for inducing favorable 
changes in lipid profile and reducing risk for CVD. Physical activity is associated with reduced 
CVD risk in the general population.19 Physical activity has also been shown to produce favorable 
modifications to lipid profile in the general population, increasing HDL and decreasing total 
cholesterol, LDL, and trigylcerides.20-22 In women, a large meta-analysis has shown that aerobic 
exercise significantly reduces total cholesterol, LDL cholesterol and triglycerides, and 
significantly increases HDL cholesterol.23 Fewer studies have been conducted in postmenopausal 
women. Although many studies in postmenopausal women have failed to find a significant effect 
of physical activity on lipid profile, the EFOPS trial found that participants randomized to 
exercise significantly reduced total cholesterol and triglyceride levels over 2 years.24,25 Among 
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breast cancer survivors, a 2010 systematic review found that exercise interventions significantly 
decreased serum triglycerides, but had no significant effect on total cholesterol, HDL, or LDL.26 
To our knowledge, no studies have examined the effect of exercise on lipid profile in breast 
cancer survivors taking AIs. 
 Given the lack of existing literature, the purpose of this analysis was to examine the 
effect of exercise versus usual care on lipid profile in sedentary postmenopausal breast cancer 
survivors taking AIs in the Hormones and Physical Exercise (HOPE) study. We hypothesized 
that exercise would improve lipid profiles, increasing HDL cholesterol and decreasing total 
cholesterol (TC), LDL cholesterol, triglycerides, LDL/HDL ratio and TC/HDL ratio. 
METHODS 
Study Population 
The 121 postmenopausal breast cancer survivors who were enrolled in the Hormones and 
Physical Exercise (HOPE) study are included in this report. Eligible women were English 
speaking, physically inactive (< 90 minutes per week of aerobic activity in past 6 months and no 
strength training in past year), had been diagnosed with hormone receptor-positive stage 0-III 
breast cancer 0.5 to 4 years before enrollment, and had physician consent to exercise. 
Participants must also have been taking an AI for at least 6 months and experiencing mild or 
greater severity arthralgia (score ≥ 3 for worst pain item on modified Brief Pain Inventory) 
associated with AI use at time of enrollment.27 Exclusion criteria included being over 75 years of 
age. 
Recruitment 
 Potentially eligible women were identified at five hospitals in Connecticut through the 
Rapid Case Ascertainment Shared Resource Center of the Yale Cancer Center (RCA) between 
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June 1, 2010, and December 30, 2012. Study staff contacted patients’ physicians for permission 
to contact the participants and approval for the patient to exercise. Following receipt of physician 
consent, an invitation letter was mailed to the participant. Within two weeks of mailing, 
participants were contacted by telephone to gauge interest and determine eligibility through a 
screening questionnaire. Women who were interested and considered to be eligible were 
scheduled for a baseline interview, where signed consent was obtained and several study 
questionnaires were completed. Final study eligibility was determined at the baseline clinic visit. 
At the conclusion of the baseline clinic visit, women were randomized to the exercise 
intervention program (N = 61) or to an attention control (health education) program (N = 60). 
 All procedures, including written informed consent, were approved by the Yale School of 
Medicine Human Investigation Committee and Connecticut Department of Public Health Human 
Investigation Committee. 
Procedures and Measures 
 At each of the baseline, 6- and 12-month clinic visits, standard questionnaires were used 
to collect information on demographics, anthropometrics, medical history and health habits. Self-
reported demographic variables collected at baseline included current age, race/ethnicity, 
education level, and marital status. Interviewer-administered questionnaires were used to 
determine time since diagnosis, time since initiating AI therapy, disease stage, use of cholesterol-
lowering medication, and history of physician-diagnosed high cholesterol. Height and weight 
measures were performed with participants in light clothing and without shoes. All measures 
were performed and recorded twice in succession, with weight (digital scale) rounded up to the 
nearest 0.1 kg and height (stadiometer) rounded up to the nearest 0.1 cm. 
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Cardiorespiratory fitness was measured with a maximal oxygen consumption (VO2 max) 
treadmill test at baseline and 12 months.28 Physical activity was assessed using a physical 
activity questionnaire (PAQ) that all participants completed at baseline and at 6 and 12 months, 
measuring the past 6 months of activity, including the type, frequency, and duration of 20 
activities.29 
 Blood samples were collected at each of the baseline, 6-month and 12-month clinic visits 
by a trained phlebotomist. Participants were instructed to fast for a minimum of 12 hours prior to 
the blood draw and the time last ate was recorded. Participants were also questioned about 
alcohol consumption within the past 48 hours. Plasma samples were centrifuged at 2,500 rpm for 
10 minutes at 4° C, then were stored at -80° C until assayed. Plasma total cholesterol, HDL, and 
triglycerides were enzymatically measured on an Alfa Wassermann ACE Alera Chemistry 
Analyzer (Alfa Wassermann, West Caldwell, NJ). 
Intervention 
 Women in the exercise intervention group were counseled to increase their physical 
activity to include twice-weekly strength training sessions and 150 minutes per week of walking 
during the 12-month intervention, based on current recommendations for cancer survivors.30 
Participants were provided with a 12-month membership to a local gym and met twice weekly 
with an American College of Sports Medicine-certified cancer exercise trainer. Supervised 
strength training sessions consisted of six common strength-training exercises, using the protocol 
developed by Schmitz et al.31 The aerobic exercise intervention consisted primarily of brisk 
walking, and could be completed at the gym or at home. Exercise started at 50% of maximal 
heart rate (determined from VO2 max testing) and increased to 60% to 80% of maximal heart 
rate over the course of the study. 
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 Women in the health education group were instructed to continue with their usual 
activities. They were provided written information emphasizing the importance of a healthy 
lifestyle and were encouraged to follow the NCI and ACS physical activity guidelines (150 
minutes per week of moderate-intensity physical activity for women diagnosed with breast 
cancer).30 Health education participants each received a one-on-one session with an exercise 
trainer and a personalized exercise prescription upon completion of the study. 
 All participants received an educational booklet prepared for the HOPE study with breast 
cancer topics of interest that were discussed monthly over the telephone (health education) or at 
an exercise session (exercise). Upon completion of the intervention, all participants were also 
given information on survivorship resources in Connecticut. 
Statistical Analyses 
 Data were analyzed according to the intention-to-treat principle. Descriptive statistics - 
Student t-test, chi-square test, and Fisher’s exact test – were used to compare the intervention 
groups at baseline. We used generalized linear models (GLM) controlling for baseline scores of 
the relevant component of the lipid profile and lipid-lowering medication use to compare the 
mean changes over time (baseline to 6-month and baseline to 12-month time points) between the 
intervention and health education group for each component of the lipid profile. Other potential 
covariates included age, race/ethnicity, BMI, cancer stage, time on AI, fasting status, and alcohol 
use. Covariates were selected for inclusion in the final models using a step-down approach, with 
a covariate retained across all of the models for each component of the lipid profile if it was a 
significant predictor (p < 0.05) of at least one component. Our primary time points were baseline, 
6 months, and 12 months. For women who did not have a follow-up blood drawn at the 6- or 12-
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month clinic visits, a conservative last observation carried forward imputation approach was 
used. 
 To evaluate the presence of a dose-response effect of the intervention, several sub-group 
analyses were performed among women in the intervention group. We examined the impact of 
attendance at the supervised sessions on lipid profile by comparing women who attended at least 
80% of sessions to those who did not. Likewise, we examined the impact of aerobic exercise 
dose on lipid profile by comparing women who participated in at least 120 minutes per week 
(i.e., 80% of the 150 minutes per week goal) of moderate-intensity aerobic exercise to those who 
did not. Finally, we performed stratified analyses by cholesterol-lowering medication status at 
baseline and baseline lipid status (above/below recommended value) to assess the presence of 
effect modification. All analyses were performed using SAS software (version 9.3; SAS 
Institute, Cary, NC), with two-sided statistical significance set at p < 0.05. 
RESULTS 
 A total of 1,537 estrogen receptor-positive breast cancer survivors were identified 
through the RCA. Screening telephone calls were completed with 1,016 women (66%). Of these 
women, 253 were not taking an AI, 407 were ineligible for other reasons, and 235 were not 
interested. The remaining 121 women were randomly assigned to the exercise intervention (N = 
61) or to the attention control (N = 60). The last 25 women recruited were enrolled into a 6-
month trial rather than the full 12-month trial, due to funding cuts. The flow of patients through 
the HOPE study has been described in more detail previously.32 
Demographic and clinical characteristics at baseline are shown in Table 1. There were no 
significant differences between the two study arms at baseline. The average age of study 
participants was 61 years, while the average BMI was 29.3 kg/m2. The average time between 
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diagnosis of breast cancer and enrollment was 3.0 years and participants had been taking AIs for 
1.8 years on average. A majority of the women were non-Hispanic white (86%), were presently 
married (53%), had completed some additional schooling after high school (37%), and were 
diagnosed with stage I disease (60%). A physician diagnosis of high cholesterol was reported by 
49 women (44%), while 43 women (36%) reported taking lipid-lowering medication. At 
baseline, the participants had a mean total cholesterol level of 198.2 mg/dL (SD 35.9), HDL 
level of 59.1 mg/dL (SD 14.3), LDL level of 115.7 mg/dL (SD 31.9), triglyceride level of 117.6 
mg/dL (SD 50.4), LDL/HDL ratio of 2.1 (SD 0.7) and TC/HDL ratio of 3.5 (SD 0.9). 
As assessed via the physical activity questionnaire, women randomized to exercise 
increased their physical activity by 159 minutes per week from baseline to 12 months, while 
women in the attention control group increased their physical activity by 49 minutes per week (p 
< 0.001). Exercisers significantly (p < 0.001) improved their cardiorespiratory fitness from 
baseline to end-of-study compared to the control group, with a 6.5% increase versus a 1.8% 
decrease, respectively. Exercisers also reduced their body weight by 2.1 kg (2.4%) from baseline 
to 12 months, compared to a 0.1 kg (0.0%) increase in the control group (p = 0.04). 
 Table 3 presents the mean baseline and adjusted 6- and 12-month change from baseline 
values by intervention group for the lipid parameters. There were no statistically significant 
differences between groups in baseline total cholesterol (p = 0.71), HDL cholesterol (p = 0.93), 
LDL cholesterol (p = 0.77), triglycerides (p = 0.83), LDL/HDL ratio (p = 0.87), or TC/HDL ratio 
(p = 0.80). LDL/HDL ratio significantly increased from baseline to 6 months in the exercise 
group compared to the attention control group (0.07 ± 0.06 vs. -0.13 ± 0.06, p = 0.036). 
Similarly, TC/HDL ratio significantly increased from baseline to 6 months in the exercise group 
compared to the attention control group (0.06 ± 0.07 vs. -0.17 ± 0.07, p = 0.038). Both ratios also 
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increased from baseline to 12 months in the exercise group compared to the attention control 
group, but these differences were not significant (p = 0.17). There were no significant differences 
between groups for 6- and 12-month change in total cholesterol, HDL, LDL and triglycerides. 
 Stratifying by lipid-lowering medication status at baseline, by baseline lipid status 
(above/below recommended value), or by AI type (steroidal/non-steroidal) resulted in no 
significant findings (data not shown). Table 4 shows the dose-response effect of attendance to 
supervised sessions on adjusted changes in lipid profile at 6 and 12 months among exercisers. 
Greater attendance to sessions was associated with decreases in triglycerides from baseline to 6 
months (-11.6 ± 11.3, p = 0.31) and from baseline to 12 months (-28.7 ± 13.9, p = 0.047). More 
minutes per week of aerobic exercise was not significantly associated with any changes in lipid 
profile (data not shown). 
DISCUSSION 
 We investigated whether a 12-month exercise intervention would have a positive effect 
on lipid levels in a population of sedentary postmenopausal breast cancer survivors taking AIs. 
We found that the atherogenic risk ratios increased from baseline to 6 months in women 
randomized to exercise, whereas these ratios decreased in women randomized to the health 
education group. A trend toward significance was observed for HDL cholesterol and 
triglycerides, with decreased levels of each lipid parameter in the exercise group compared to the 
control group at both 6 and 12 months. A dose-response inverse relationship between attendance 
at supervised sessions and triglyceride level was also observed, with increased attendance (≥ 
80% of sessions) associated with a decrease in triglycerides. A decrease in triglycerides due to 
exercise is consistent with the prior literature in postmenopausal women and breast cancer 
survivors. 
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Increases in the atherogenic risk ratios are not desirable, as these ratios are positively 
associated with CVD risk, and have greater predictive value than isolated lipid parameters.33 One 
mechanism by which exercise could affect lipid concentrations in this way is through a negative 
effect on body fat, and ultimately circulating estrogen levels. A previous randomized trial 
showed that exercise can lower levels of circulating estrogens in a clinically significant way in a 
population of previously sedentary, overweight/obese postmenopausal women.34 As inhibition of 
estrogen synthesis is a primary goal of treatment of hormone receptor-positive breast cancer, 
patients treated with AIs experience a high level of estrogen deprivation.35 It is possible that 
exercise exacerbates this decrease in estrogen levels through its effect in decreasing body fat, 
thus further increasing the risk of altered lipid profiles. This is supported by the fact that 
participants randomly assigned to exercise reduced their body weight by 2.1 kg on average, and 
that, after controlling for change in BMI, there were no longer significant differences in 
LDL/HDL ratio and TC/HDL ratio between groups. 
Caution should be used in interpreting these data, as alteration of lipid levels is only one 
way in which exercise may impact cardiovascular risk. Results from large epidemiological 
studies have repeatedly shown that exercise reduces the risk for CVD independent of changes in 
cardiovascular risk markers, including BMI and lipids.36 
 Prior tamoxifen use, type of AI used, and inclusion of patients on lipid-lowering 
medications may have impacted the results. Use of tamoxifen reduces LDL cholesterol and 
previous studies have reported a washout effect for tamoxifen on lipid levels, with Bell et al. 
finding that prior use of tamoxifen was a significant independent predictor of increased LDL 
cholesterol.16,17 It is unclear if we should expect a similar washout effect in the current study, 
given that all study participants had been taking AIs for at least 8 months at time of enrollment. 
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By contrast, participants with prior tamoxifen use in the Bell et al. and Wasan et al. studies were 
withdrawn from adjuvant tamoxifen just before entry into the two trials. Significant increases in 
LDL cholesterol were seen at 3 and 6 months, respectively. We did not collect information on 
participants’ prior tamoxifen use. The type of AI – steroidal (exemestane) or non-steroidal 
(letrozole or anastrozole) – was an independent predictor of change in HDL, LDL/HDL ratio and 
TC/HDL ratio in our study, with use of a steroidal AI significantly associated with decreased 
HDL, increased LDL/HDL ratio and increased TC/HDL ratio across both groups. Similarly, use 
of lipid-lowering medications was significantly associated with a decrease in LDL and a 
decrease in LDL/HDL ratio. Stratifying by type of AI used or use of lipid-lowering medications 
did not result in any significant findings for the effect of exercise, although this may indicate that 
the study was not powered for stratified analyses. 
 Baseline lipid parameters tended to be lower than values reported in previous studies of 
postmenopausal breast cancer patients, with lower decreased average total cholesterol, HDL and 
LDL and higher average triglycerides in our study.16,17 This may reflect the higher usage of lipid-
lowering medication in this population. In our sample, 17.2% of women aged 40-59, 50.8% of 
women aged 60-74, and 100% of women aged 75 and over used a prescription lipid-lowering 
medication. This usage is higher than that of women in the general population within each age 
stratum.37 
 To our knowledge, this is the first study to examine the effect of exercise on lipid 
parameters in a sample of postmenopausal breast cancer survivors exclusively taking AIs. A 
major strength of our study is the strong methodological design, including randomization with an 
attention control group, a population with variable BMI, large sample size, population-based 
recruitment, and 12-month follow-up period. An additional strength is the high adherence to the 
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exercise intervention. Our study had several limitations, however. We lacked information about 
other risk factors associated with changes in lipid profile, most notably prior tamoxifen use. 
Women in the HOPE study had been taking AIs for 8 months to 4 years at time of enrollment, 
and this variability may have had an effect on lipid profile independent from exercise, although 
the amount of time on AIs was not a significant predictor of change in any of the lipid 
parameters. If we had enrolled women prior to initiation of AIs, and measured change in lipids 
with exercise during the first year of AI use, we may have observed different effects of exercise. 
Finally, the statistical power for stratified analyses was likely limited by the sample size of the 
study. 
 In conclusion, we observed no effect of exercise on the lipid profile of postmenopausal 
women with breast cancer taking aromatase inhibitors, and an unfavorable effect of exercise on 
the lipid ratios; however this effect become non-significant after adjusting for change in BMI. 
Further research is needed to examine the impact of exercise on lipid levels and CVD risk in 
breast cancer survivors initiating AI use. 
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Table 1.  Baseline Characteristics of Randomly Assigned Participants in HOPE Studya 
    
Characteristic Exercise Intervention  (N=61)b 
Attention Control 
(N=60)b P
c 
Age (years) 62.0 ± 7.0 60.5 ± 7.0 0.25 
Race/ethnicity   0.67 
     Non-Hispanic white 53 (86.9) 51 (85.0)  
     Non-Hispanic black 6 (9.8) 4 (6.7)  
     Hispanic 1 (1.6) 3 (5.0)  
     Other 1 (1.6) 2 (3.3)  
Education     0.46 
     ≤ High school graduate 6 (9.8) 9 (15.0)   
     Some school after high school 20 (32.8) 25 (41.7)   
     College graduate 15 (24.6) 10 (16.7)   
     ≥ Some graduate school 20 (32.8) 16 (26.7)   
Marital status   0.79 
     Never Married/Divorced/Widowed 28 (45.9) 29 (48.3)  
     Presently married 33 (54.1) 31 (51.7)  
Time since diagnosis (years) 2.7 ± 3.1 3.3 ± 3.9 0.38 
Time since initiating AI therapy (years) 1.9 ± 1.9 1.8 ± 1.3 0.89 
AI type     1.00 
     Anastrozole 30 (49.2) 30 (50.0)   
     Letrozole 26 (42.6) 26 (43.3)   
     Exemestane 5 (8.2) 4 (6.7)   
Disease stage     0.87 
     0 1 (1.6) 0 (0.0)   
     I 36 (59.0) 37 (61.7)   
     II 18 (29.5) 19 (31.7)   
     III 6 (9.8) 4 (6.7)   
Body mass index (kg/m2) 30.0 ± 6.8 28.7 ± 5.5 0.27 
Taking lipid-lowering medication     0.80 
     Yes 21 (34.4) 22 (36.7)   
     No 40 (65.6) 38 (63.3)   
Physician-diagnosed high cholesterol     0.92 
     Yes 25 (44.6) 24 (43.6)   
     No 31 (55.4) 31 (56.4)   
a Table values are mean ± SD for continuous variables and n (column %) for categorical variables 
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding 
c P-value is for t-test (continuous variables), χ2 test (other categorical variables), or Fisher's exact test (cell 
counts < 5) 
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Table 2. Physical Activity, Cardiorespiratory Fitness, and Body Weight Changes 
in HOPE Studya 
          
Measure Exercise Intervention 
(N=61) 
Attention Control 
(N=60)   
P 
Physical activity questionnaire, 
minutes per week         
     Baseline 54.8 ± 93.0 60.7 ± 99.0   0.74 
     12 months 222.1 ± 118.6 103.6 ± 104.7 < 0.001* 
     Change 159 ± 136 49 ± 86 < 0.001* 
          Percent reporting ≥ 150 70 6     
VO2 max, ml/kg per minute 
         Baseline 23.0 ± 5.3 23.1 ± 3.5 
 
0.88 
     12 months 24.6 ± 5.5 23.0 ± 4.7 
 
0.17 
     Change 1.5 ± 2.1 -0.4 ± 2.7 < 0.001* 
          Percent change 6.5 ± 3.7 -1.8 ± 11.2 
 
0.001* 
Body weight, kg         
     Baseline 78.5 ± 18.1 75.5 ± 14.5   0.32 
     Change -2.1 ± 4.3 0.1 ± 3.6   0.014* 
          Percent change -2.4 ± 5.4 0.0 ± 4.8   0.37 
a Table values are mean ± SD  
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Table 3.  Effect of Exercise Versus Usual Care on Lipids at Baseline and Changes at 6 and 
12 Months (Adjusted for baseline value, lipid-lowering medication use, AI type, race, 
BMI, disease stage, and alcohol use)a,b 
  
   
  
Outcome Exercise Intervention (N=61)c 
Attention Control 
(N=60)d 
Treatment Effect 
(exercise minus 
control) 
  P 
Total Cholesterol         
     Baseline 197.0 ± 4.6 199.5 ± 4.7 -2.5 ± 6.5 0.71 
     6-month change 3.8 ± 2.9 1.6 ± 2.9 2.2 ± 4.2 0.60 
     12-month change 1.3 ± 3.4 3.8 ± 3.4 -2.5 ± 5.0 0.61 
HDL Cholesterol     
     Baseline 59.0 ± 1.8 59.2 ± 1.9 -0.2 ± 2.6 0.93 
     6-month change 0.7 ± 1.3 2.2 ± 1.3 -1.5 ± 2.0 0.45 
     12-month change -0.6 ± 1.5 1.6 ± 1.5 -2.2 ± 2.3 0.35 
LDL Cholesterol         
     Baseline 114.8 ± 4.0 116.5 ± 4.2 -1.7 ± 5.8 0.77 
     6-month change 3.6 ± 2.5 -0.3 ± 2.5 4.0 ± 3.7 0.28 
     12-month change 2.6 ± 3.4 0.9 ± 3.4 1.7 ± 5.0 0.74 
Triglycerides     
     Baseline 116.7 ± 6.6 118.6 ± 6.4 -1.9 ± 9.2 0.83 
     6-month change -2.7 ± 4.3 -2.5 ± 4.4 -0.2 ± 6.4 0.98 
     12-month change -0.3 ± 5.9 3.7 ± 5.9 -4.0 ± 8.7 0.64 
LDL/HDL Ratio         
     Baseline 2.05 ± 0.09 2.07 ± 0.09 -0.02 ± 0.13 0.87 
     6-month change 0.07 ± 0.06 -0.13 ± 0.06 0.19 ± 0.09 0.036* 
     12-month change 0.09 ± 0.10 -0.11 ± 0.10 0.20 ± 0.14 0.17 
TC/HDL Ratio     
     Baseline 3.48 ± 0.11 3.52 ± 0.11 -0.04 ± 0.16 0.80 
     6-month change 0.06 ± 0.07 -0.17 ± 0.07 0.22 ± 0.10 0.038* 
     12-month change 0.11 ± 0.11 -0.12 ± 0.11 0.23 ± 0.16 0.17 
a Table values are mean ± SE 
b 6- and 12-month values are change from baseline 
c N=48 at 12 months 
d N=48 at 12 months 
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Table 4.  Effect of Attendance to Supervised Sessions on Lipids at Baseline and Changes at 
6 and 12 Months (Adjusted for baseline value, lipid-lowering medication use, disease stage, 
and alcohol use)a,b 
  
   
  
Outcome High Attendance (≥80%) [N=34]c 
Low Attendance 
(<80%) [N=27]d 
Treatment 
Effect (high 
minus low) 
  P 
Total Cholesterol         
     Baseline 198.8 ± 6.3 194.8 ± 6.7 4.0 ± 9.2 0.66 
     6-month change 4.1 ± 4.2 1.8 ± 4.7 2.3 ± 6.6 0.73 
     12-month change 2.0 ± 5.5 3.2 ± 5.7 -1.2 ± 8.3 0.89 
HDL Cholesterol     
     Baseline 61.5 ± 2.5 55.7 ± 2.5 5.8 ± 3.6 0.11 
     6-month change 1.0 ± 2.1 0.0 ± 2.4 0.9 ± 3.3 0.78 
     12-month change -0.7 ± 2.6 -0.4 ± 2.7 -0.3 ± 3.9 0.95 
LDL Cholesterol         
     Baseline 114.1 ± 5.9 115.7 ± 5.4 -1.5 ± 8.2 0.85 
     6-month change 4.8 ± 3.6 1.2 ± 4.1 3.6 ± 5.7 0.53 
     12-month change 5.9 ± 5.5 1.2 ± 5.8 4.7 ± 8.4 0.58 
Triglycerides     
     Baseline 116.3 ± 9.0 117.1 ± 9.9 -0.9 ± 13.5 0.95 
     6-month change -8.9 ± 7.1 2.7 ± 8.1 -11.6 ± 11.3 0.31 
     12-month change -16.7 ± 9.2 12.0 ± 9.6 -28.7 ± 13.9 0.047* 
LDL/HDL Ratio         
     Baseline 1.97 ± 0.14 2.16 ± 0.13 -0.19 ± 0.19 0.31 
     6-month change 0.09 ± 0.09 0.01 ± 0.10 0.08 ± 0.14 0.59 
     12-month change 0.12 ± 0.16 0.08 ± 0.17 0.04 ± 0.24 0.88 
TC/HDL Ratio     
     Baseline 3.38 ± 0.16 3.60 ± 0.16 -0.22 ± 0.23 0.32 
     6-month change 0.07 ± 0.10 0.01 ± 0.12 0.05 ± 0.17 0.75 
     12-month change 0.06 ± 0.18 0.14 ± 0.18 -0.08 ± 0.27 0.76 
a Table values are mean ± SE 
b 6- and 12-month values are change from baseline 
c N=25 at 12 months 
d N=23 at 12 months 
 
